1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)
Authors:
- D. MilesDMD. Miles
- D. CameronDCD. Cameron
- I. BondarenkoIBI. Bondarenko
- M. LyudmilaMLM. Lyudmila
- J.C. AlcedoJAJ.C. Alcedo
- R.I. LopezRLR.I. Lopez
- S.A. ImSIS.A. Im
- J.L. CanonJCJ.L. Canon
- Y. ShparykYSY. Shparyk
- D. YardleyDYD. Yardley
- N. MasudaNMN. Masuda
- J. RoJRJ. Ro
- 1 September 2015
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S287-S288